All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Nivolumab, a programmed death protein 1 (PD-1) antibody, is under accelerated approval by the US Food and Drug administration (FDA)1 for patients with relapsed and refractory (R/R) classical Hodgkin lymphoma (cHL), who have relapsed or progressed after autologous stem cell transplant (ASCT). For newly-diagnosed cHL, multiagent chemotherapy is the current standard of care.2,3 This has proved a good treatment strategy for early-stage, naive cHL but remains suboptimal for advanced-stage patients.2
The CheckMate 205 (NCT02181738) phase II trial4 demonstrated that nivolumab monotherapy has an acceptable safety profile and leads to good and durable responses in patients with R/R cHL. In an extended cohort (Cohort D) of the CheckMate 205 study, single-agent nivolumab followed by a period of nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (N-AVD), was evaluated for safety and efficacy in advanced-stage previously-untreated cHL. These results were published in the Journal of Clinical Oncology3 by Radhakrishnan Ramchandren from the University of Tennessee, Knoxville, TN, USA, and colleagues on 21 May 2019.
The primary endpoints of this analysis were safety and tolerability, measured as an increase in Grade 3–5 treatment-emergent adverse events (TEAEs) between first dose and one month after last dose. Secondary endpoints, included overall response rate (ORR) and complete response (CR) rate, as assessed by an independent radiology review committee (IRC).
Baseline characteristic |
Patients (N = 51) |
---|---|
Median age (range) |
37 (18–87) years |
Ann Arbor stage: II III IV |
20% (n= 10) 24% (n= 12) 57% (n= 29) |
International Prognostic Index (IPI) score: 0–1 2–3 ≥4 Unreported |
24% (n= 12) 41% (n= 21) 25% (n= 13) 10% (n= 5) |
Bulky disease |
31% (n= 16) |
Extranodal disease |
49% (n= 25) |
|
At end of nivolumab monotherapy |
After two N-AVD combination cycles |
At end of N-AVD combination treatment (EOT) |
---|---|---|---|
ORR (95% CI) |
69% (54–81) |
90% (79–97) |
84% (71–93) |
CR rate (95% CI) |
18% (8–31) |
51% (37–65) |
67% (52–79) |
Tumor lesion burden reduction >50% |
71% (35/49) |
98% (45/46) |
100% (46/46) |
Progressive disease (PD) |
- |
- |
6% |
Nivolumab monotherapy, followed by a period of nivolumab in combination with AVD chemotherapy, showed a manageable safety profile and led to very good responses in previously-untreated, advanced-stage patients with cHL.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox